Abstract: Techniques described herein relate to a method for performing state management services for composed information handling systems. The method includes determining that at least one control resource set is not associated with a distributed state storage system; instantiating the distributed state storage system using first additional computing resources; registering the at least one control resource set with the distributed state storage system; preparing the at least one control resource set to perform a first portion of the state management services using the distributed state storage system; determining that the at least one control resource set is not associated with an audit storage; instantiating the audit storage using second additional computing resources; registering the at least one control resource set with the audit storage; and preparing the at least one control resource set to perform a second portion of the state management services using the audit storage.

Abstract: An extracorporeal blood treatment device and a method are provided for removing a secondary membrane formed on a semipermeable membrane of a dialyzer during an extracorporeal blood treatment. The extracorporeal blood treatment device operates in a first operating mode in which a dialysate outlet valve is open such that dialysate flows through a dialyzer feed line, through a dialysate chamber, and into and through a dialyzer discharge line. The extracorporeal blood treatment device operates in a second operating mode to remove the secondary membrane from the semipermeable membrane. During the second operating mode, the dialysate outlet valve is closed for a duration of time such that dialysate is prevented from flowing through the dialyzer discharge line. A backflush procedure results wherein a volume of dialysate passes from the dialysate chamber through the semipermeable membrane and into the blood chamber.

Abstract: A system for providing computer implemented services using information handling systems includes persistent storage and a system control processor manager. The system control processor manager instantiates composed information handling systems using the information handling systems; monitors, using system control processors of the composed information handling systems, operation of the composed information handling systems to obtain operation information; makes a determination, based on the operation information, that the computing implemented services provided by the composed information handling systems are substandard; and in response to the determination: manages operation of the composed information handling systems to provide standards compliant computer implemented services by modifying a composition of at least one of the composed information handling systems using a system control processor of the system control processors.

Abstract: The present invention provides compositions and methods for lowering blood glucose. More specifically, the present invention provides compositions comprising a complex comprising IF and B12 conjugated to a peptide comprising a GLP-1 agonist. Advantageously, the composition may be delivered subcutaneously.

Abstract: A method of making a hydroxyl-terminated thioketal diol is provided, the method comprising reacting a thioketal ester with a non-pyrophoric reducing agent to form a hydroxyl-terminated thioketal diol. The hydroxyl-terminated thioketal diol can be 2,2-(propane-2,2-diylbis(sulfanediyl)) diethanol. The non-pyrophoric reducing agent can be a sodium aluminum hydride, for example, sodium bis (2-methoxyethoxy)aluminum hydride. The thioketal ester can be dimethyl 2,2-(propane-2,2-diylbis(sulfanediyl)) diacetate. A biodegradable matrix prepared by reacting a hydroxyl-terminated thioketal diol with an isocyanate is provided. A method of making a biodegradable polyurethane composite is also provided.

Abstract: The present disclosure provides pharmaceutical formulations and methods for delivering a therapeutic, diagnostic, or imaging agent to CD206. In an aspect, the present disclosure encompasses a pharmaceutical formulation for administration. The pharmaceutical formulation comprises a recombinantly produced intrinsic factor (IF), wherein the IF has a glycosylation pattern that enables binding to CD206.

Abstract: The invention involves the coupling of compounds that can be bound by Haptocorrin (R-binder; Transcobalamin I; HC) to a target drug to improve pharmacokinetics, avoid undesirable side effects, and/or modify CNS access and localization. The pharmaceutical effect may be improved by conjugating the drug to haptocorrin binding substrate. This allows the conjugate to become bound to unsaturated haptocorrin in the blood, thereby protecting the drug from metabolism or excretion to increase protein half-life while not interfering with the efficacy of the protein drug. The conjugation may additionally prevent the drug from reaching the central nervous system or modify where the drug localizes and produces undesirable side effects such as nausea or hypophagia. Such a route also would prevent, in all case save for actual vitamin B12, binding by serum transcobalamin II (TCII), and thus not cause B12 deficiency with long term use.

Abstract: The present invention relates to engineered peptides and to methods of making engineered peptides. The present invention also relates to methods of treatment comprising administration of the engineered peptides to a subject in need thereof.

Abstract: The present invention provides compositions and methods for lowering blood glucose. More specifically, the present invention provides compositions comprising a complex comprising IF and B12 conjugated to a peptide comprising a GLP-1 agonist. Advantageously, the composition may be delivered subcutaneously.

Abstract: The invention involves the coupling of compounds that can be bound by Haptocorrin (R-binder; Transcobalamin I; HC) to a target drug to improve pharmacokinetics, avoid undesirable side effects, and/or modify CNS access and localization. The pharmaceutical effect may be improved by conjugating the drug to haptocorrin binding substrate. This allows the conjugate to become bound to unsaturated haptocorrin in the blood, thereby protecting the drug from metabolism or excretion to increase protein half-life while not interfering with the efficacy of the protein drug. The conjugation may additionally prevent the drug from reaching the central nervous system or modify where the drug localizes and produces undesirable side effects such as nausea or hypophagia. Such a route also would prevent, in all case save for actual vitamin B12, binding by serum transcobalamin II (TCII), and thus not cause B12 deficiency with long term use.

Abstract: The present disclosure relates to metal di-amino acid chelates and metal tri-amino acid chelates.

Abstract: The present disclosure relates to metal di-amino acid chelates and metal tri-amino acid chelates.

Abstract: A head-mounted display device is provided, including an at least partially see-through display, an electrical device, and a flexible printed circuit board (FPC) arranged on a surface of a see-through portion of the display. The FPC may include a plurality of electrical traces electrically coupled to the electrical device. Each electrical trace may be separated from at least one other electrical trace by one or more respective see-through gaps. The FPC may further include a transparent material arranged between the electrical traces in each see-through gap.

Abstract: A method of making a hydroxyl-terminated thioketal diol is provided, the method comprising reacting a thioketal ester with a non-pyrophoric reducing agent to form a hydroxyl-terminated thioketal diol. The hydroxyl-terminated thioketal diol can be 2,2-(propane-2,2-diylbis(sulfanediyl)) diethanol. The non-pyrophoric reducing agent can be a sodium aluminum hydride, for example, sodium bis (2-methoxyethoxy)aluminum hydride. The thioketal ester can be dimethyl 2,2-(propane-2,2-diylbis(sulfanediyl)) diacetate. A biodegradable matrix prepared by reacting a hydroxyl-terminated thioketal diol with an isocyanate is provided. A method of making a biodegradable polyurethane composite is also provided.

Abstract: A method of making a hydroxyl-terminated thioketal diol is provided, the method comprising reacting a thioketal ester with a non-pyrophoric reducing agent to form a hydroxyl-terminated thioketal diol. The hydroxyl-terminated thioketal diol can be 2,2-(propane-2,2-diylbis(sulfanediyl)) diethanol. The non-pyrophoric reducing agent can be a sodium aluminum hydride, for example, sodium bis(2-methoxyethoxy)aluminum hydride. The thioketal ester can be dimethyl 2,2-(propane-2,2-diylbis(sulfanediyl)) diacetate. A biodegradable matrix prepared by reacting a hydroxyl-terminated thioketal diol with an isocyanate is provided. A method of making a biodegradable polyurethane composite is also provided.

Abstract: A head-mounted display device is provided, including an at least partially see-through display, an electrical device, and a flexible printed circuit board (FPC) arranged on a surface of a see-through portion of the display. The FPC may include a plurality of electrical traces electrically coupled to the electrical device. Each electrical trace may be separated from at least one other electrical trace by one or more respective see-through gaps. The FPC may further include a transparent material arranged between the electrical traces in each see-through gap.

Abstract: A computer-assisted method to provide timely multi-channel notification of treatments to healthcare providers and patients, the method including receiving de-identified longitudinal medical records, treatment prescription records of healthcare providers, and notification data. Relationships between the healthcare providers, the anonymized patients, and the notifications are identified using the de-identified longitudinal medical records, the treatment prescription records of the healthcare providers, and the notification data. An impact of notifications being received by both the healthcare provider for the anonymized patient and the anonymized patient on whether the anonymized patient received the treatment is determined.

Abstract: A method of making a hydroxyl-terminated thioketal diol is provided, the method comprising reacting a thioketal ester with a non-pyrophoric reducing agent to form a hydroxyl-terminated thioketal diol. The hydroxyl-terminated thioketal diol can be 2,2-(propane-2,2-diylbis(sulfanediyl)) diethanol. The non-pyrophoric reducing agent can be a sodium aluminum hydride, for example, sodium bis(2-methoxyethoxy)aluminum hydride. The thioketal ester can be dimethyl 2,2-(propane-2,2-diylbis(sulfanediyl)) diacetate. A biodegradable matrix prepared by reacting a hydroxyl-terminated thioketal diol with an isocyanate is provided. A method of making a biodegradable polyurethane composite is also provided.

Abstract: The present invention relates to the digestion of peptides by pancreatic proteases and, more specifically, to compositions and methods for protecting against protease digestion.

Abstract: A light source includes a side-emitting, light emitting diode (LED) that is mounted on a printed circuit board (PCB) or other substrate. The LED is used to illuminate a target such as a sensor or the like. In order to increase the amount of illumination emitted by the LED that reaches the target, a reflector is located on the PCB. The reflector receives light that is emitted by the LED and directed toward the PCB and not the target. This light, which would otherwise be lost, is reflected by the reflector and re-directed toward the target. By reducing the amount of light is lost, the amount of light reaching the target can be increased without a commensurate increase in the current supplied to the LED.